This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Ming Wang, PhD, MBA
Founder, President and CEO at Phanes Therapeutics


Dr. Ming Wang is Founder, President and CEO of Phanes Therapeutics, Inc. based in San Diego, California, USA and Songshan Lake, Guangdong, China. The company is focused on drug discovery and early development to treat cancer and metabolic complications. Ming was formerly Vice President and Disease Area Leader of Diabetes/Metabolism in Janssen, the pharmaceutical sector of Johnson & Johnson, with global responsibility for the diabetes portfolio (from discovery stage to phase 2). Previously, Ming was President and Chief Operating Officer and a member of the Board of Directors of Gan & Lee Pharmaceuticals, a biotech pioneer in China focused on insulin-based therapies where he helped grow combined annual sales to ~$100 million in China, Latin America and Southeast Asia. He also led the company to expand their operations to the US through initiation of clinical trials with their biosimilar drug insulin glargine, eventually leading to the recent global deal with Sandoz. Prior to that, Ming was Executive Director and Head of Diabetes Research at Amgen where he headed a group of ~50 scientists located in Amgen’s headquarter (Thousand Oaks) and San Francisco, working on developing novel therapies for metabolic diseases. Before joining Amgen, Ming championed drug discovery programs in cardiovascular and metabolic diseases and managed corporate partnerships in Parke-Davis, Pfizer and Pharmacia. 

Ming served on multiple advisory boards, including the Scientific Advisory Board (SAB) of Amgen Ventures. He is a frequent organizer and speaker of biotech and pharma conferences and has 59 publications and a book entitled “Metabolic Syndrome: underlying mechanisms and drug therapies” (publisher: John Wiley & Sons, Inc.). He is an Associate Editor of Frontiers in Experimental Pharmacology and Drug Discovery. He holds a PhD in Biochemistry and a MBA in General Management.